DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20170314

Drug targets: ligand and voltage gated ion channels

Nilan T. Jacob

Abstract


The elucidation of a drug target is one of the earliest and most important steps in the drug discovery process. Ion channels encompassing both the ligand gated and voltage gated types are the second most common drug targets after G-Protein Coupled Receptors (GPCR). Ion channels are basically pore forming membrane proteins specialized for conductance of ions as per the concentration gradient. They are further broadly classified based on the energy (ATP) dependence into active ion channels/pumps and passive ion channels. Gating is the regulatory mechanism of these ion channels by which binding of a specific molecule or alteration in membrane potential induces conformational change in the channel architecture to result in ion flow or its inhibition. Thus, the study of ligand and voltage gated ion channels becomes an important tool for drug discovery especially during the initial stage of target identification. This review aims to describe the ligand and voltage gated ion channels along with discussion on its subfamilies, channel architecture and key pharmacological modulators.


Keywords


Drug targets, Ion channels, Ligand gated ion channels, Receptor pharmacology, Voltage gated ion channels

Full Text:

PDF

References


Overington JP, Lazikani BA, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5:993-6.

Kornreich BG. The patch clamp technique: Principles and technical considerations. J Vet Cardiol. 2007;9:25-37.

Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997;20:92-8.

Samson AO, Levitt M. Inhibition mechanism of the acetylcholine receptor by alpha-neurotoxins as revealed by normal-mode dynamics. Biochemistry. 2008;47:4065-70.

Benzodiazepine and psychotics. Georgetown University school of Medicine. 2016 [cited 2016 Nov 19] Available fromhttps://www.studyblue.com/notes/note/n/benzodiazepine-psychotics/deck/9685444.

Johnston GA. GABAA receptor pharmacology. Pharmacol Ther. 1996;69:173-98.

Niesler B. 5-HT(3) receptors: potential of individual isoforms for personalised therapy. Curr Opin Pharmacol. 2011;11:81-6.

Lynch JW. Molecular structure and function of the glycine receptor chloride channel. Physiol Rev. 2004;84:1051-95.

Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51:7-61.

Whitlock JR, Heynen AJ, Shuler MG, Bear MF. Learning induces long-term potentiation in the hippocampus. Science. 2006;313:1093-7.

Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011;11:56-63.

Schematic diagram of NMDA receptor complex. Anaesthesia UK. 2016 [cited 2016 Nov 19] Available from http://www.frca.co.uk/article.aspx?articleid=100515.

Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol. 2007;7:39-47.

Reynolds LM, Cochran SM, Morris BJ, Pratt JA, Reynolds GP. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophr Res. 2005;73:147-52.

Mikoshiba K. IP3 receptor/Ca2+ channel: from discovery to new signaling concepts. J Neurochem. 2007;102:1426-46.

Bultynck G, Sienaert I, Parys JB, et al. Pharmacology of inositol trisphosphate receptors. Eur J Physiol. 2003;445:629-42.

Hanukoglu I, Hanukoglu A. Epithelial sodium channel (ENaC) family: Phylogeny, structure-function, tissue distribution, and associated inherited diseases. Gene. 2016;579:95-132.

Boscardin E, Alijevic O, Hummler E, Frateschi S, Kellenberger S. The function and regulation of acid-sensing ion channels (ASICs) and the epithelial Na(+) channel (ENaC): IUPHAR Review 19. Br J Pharmacol. 2016;173:2671-701.

Syed NH, Kennedy C. Pharmacology of P2X receptors. WIREs Membr Transp Signal. 2012;1:16-30.

Rodrigo GC, Standen NB. ATP-sensitive potassium channels. Curr Pharm Des. 2005;11:1915-40.

Triggle DJ. The pharmacology of ion channels: with particular reference to voltage-gated Ca2+ channels. Eur J Pharmacol. 1999;375:311-25.

Mechanism of voltage gated ion channels. 2016 [cited 2016 Nov 19] Available from https://cnx.org/contents/FPtK1zmh@8.25:fEI3C8Ot@10/Preface.

Yu FH, Catterall WA. Overview of the voltage-gated sodium channel family. Genome Biol. 2003;4:207.

Lodish H, Berk A, Matsudaira P. Molecular Cell Biology. 6th edition. 2008.

Dunlap K, Luebke JI, Turner TJ. Exocytotic Ca2+ channels in mammalian central neurons. Trends Neurosci. 1995;18:89-98.

Khosravani H, Zamponi GW. Voltage-Gated Calcium Channels and Idiopathic Generalized Epilepsies. Physiol Rev. 2006;86:941-66.

Belardetti F, Zamponi GW. Calcium channels as therapeutic targets. WIREs Membr Transp Signal. 2012;1:433-51.

Yellen G. The voltage-gated potassium channels and their relatives. Nature. 2002;419:35-42.

Wulff H, Castle NA, Pardo LA. Voltage-gated Potassium Channels as Therapeutic Drug Targets. Nat Rev Drug Discov. 2009;8:982-1001.

Zucchi R, Ronca-Testoni S. The sarcoplasmic reticulum Ca2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol Rev. 1997;49:1-51.

Smani T, Shapovalov G, Skryma R, Prevarskaya N, Rosado JA. Functional and physiopathological implications of TRP channels. Biochim Biophys Acta. 2015;1853:1772-82.

Rahman MS, Kwon WS, Pang MG. Calcium Influx and Male Fertility in the Context of the Sperm Proteome: An Update. 2014:841615.

Kaupp UB, Seifert R. Cyclic Nucleotide-Gated Ion Channels. Physiol Rev. 2002;82:769-824.

Decoursey TE. Voltage-Gated Proton Channels and Other Proton Transfer Pathways. Physiol Rev. 2003;83:475-579.